F Jafari; Sh Moradi; MA Nilforoush Zadeh; R Derakhshan; N Ansari
Volume 9, Issue 3 , 2006, , Pages 211-216
Abstract
Background and aim: Cutaneous leishmaniasis is an endemic disease in Iran. Although there are many different treatments for this disease, there is not any effective treatment yet. Since there has been a number of different reports on the effectiveness of Cassia fistula plant in the treatment of leishmaniasis, ...
Read More
Background and aim: Cutaneous leishmaniasis is an endemic disease in Iran. Although there are many different treatments for this disease, there is not any effective treatment yet. Since there has been a number of different reports on the effectiveness of Cassia fistula plant in the treatment of leishmaniasis, the efficacy of concentrated boiled extract and hydro alcoholic extract of Cassia fistula on the leishmaniasis disease was compared with intralesional injection of Glucantime in this study.Materials and Methods: In this randomized clinical trial a total of 165 patients, 6 to 60 years old, who had a positive leishmania smear refered to the Isfahan Skin and Leishmaniasis Research Center were divided into three groups using list of random numbers and were treated with: concentrated boiled extract of Cassia fistula, hydroalcholic extract of Cassia fistula, or intralesional injection of Glucantime. The patients were treated for 4 weeks and followed for three months after the study started. The efficacy of treatment was reported as complete cure, partial improvement and no improvement on the basis of clinical and parasitological evidence.Results: In the present study 63/6% of patients treated with the concentrated boiled extract, 52/7% of the hydroalcoholic extract and 45/5% of the Glucantime group were men. 22 patients (40%) of the concentrated boiled extract of Cassia fistula, 20 pateints (36/4%) of the hydroalcoholic extract of Cassia fistula group and 36 patients (65/5%) of the Glucantime group showed complete cure. The efficacy in the third group was much more than the first (P<0.02) and second groups (P<0.005), but there was not any difference between concentrated boiled extract and hydroalcoholic extract of Cassia fistula.Conclusion: The results of this study showed that this plant might be used topically along with Glucantime for decreasing the time and dose of treatment with Glucantime.
MA Nilforoush Zadeh; Sh Moradi; R Derakhshan; E Haft Baradaran; F Jafari
Volume 9, Issue 3 , 2006, , Pages 221-226
Abstract
Background and aim: Cutaneous leishmaniasis (CL) is an edemic disease widely spread in Iran. Although several treatments have been tried, none has been found as simple and effective. Honey has been used in the treatment of chronic ulcers and its anti-leishmanial effects have also been reported. So we ...
Read More
Background and aim: Cutaneous leishmaniasis (CL) is an edemic disease widely spread in Iran. Although several treatments have been tried, none has been found as simple and effective. Honey has been used in the treatment of chronic ulcers and its anti-leishmanial effects have also been reported. So we assessed the efficacy of honey in acute CL.Materials and Methods: In a randomized clinical trial, 100 patients with CL referred to Skin and Leishmaniasis Research Center were treated with either weekly intra-lesional injection of Glucantime alone or combined with twice daily topical application of honey. The patients were evaluated clinically 2 ,3 and 4 months after treatment.Results: Ninety patients completed the study, forty-five patients were treated in each group. At the end of trial, 32 patients (71/1%) of these treated with Glucantime alone and 23 patients (51/1%) treated with honey were cured (P=0.04).Conclusion: Drug interference and inhibition of bioavailability of Glucantime by honey may decrease the efficacy of Glucantime in treatment of CL.
G Sadeghian; MA Nilforoush Zadeh
Volume 9, Issue 1 , 2006, , Pages 17-21
MA Nilforoush Zadeh; G Sadeghian; F Jafari; AR Firooz; Sh Moradi; R Derakhshan
Volume 9, Issue 1 , 2006, , Pages 35-39
MA Nilforoush Zadeh; F Jafari; N Ansari; Z Nilforoushan; AR Firooz
Volume 8, Issue 5 , 2005, , Pages 340-346
MA Nilforoush Zadeh; F Jafari; Sh Rafiei
Volume 8, Issue 5 , 2005, , Pages 358-362
G Sadeghian; MA Nilforoush Zadeh; M Motevali Emami
Volume 8, Issue 4 , 2005, , Pages 251-255
Abstract
Background and objective: Different local and systemic modalities are suggested in the treatment of cutaneous leishmaniasis, but the pentavalent antimony compounds are still considered as the first line of treatment. Regarding to increase in clinical drug resistance and adverse effects, efforts to find ...
Read More
Background and objective: Different local and systemic modalities are suggested in the treatment of cutaneous leishmaniasis, but the pentavalent antimony compounds are still considered as the first line of treatment. Regarding to increase in clinical drug resistance and adverse effects, efforts to find a more effective and safer drug is continuing. The objective of this study was to compare the effect of intra-lesional hypertonic sodium chloride solution and intra-lesional meglumine antimoniate injections in the treatment of cutaneous leishmaniasis.Materials and Methods: This randomized controlled clinical trial with simple sampling method was performed on 72 patients with cutaneous leishmaniasis. The patients were randomly divided in two groups. One group was treated with intra-lesional hypertonic sodium chloride solution and the other one was treated with intra-lesional meglumine antimoniate injections at weekly intervals for 6 to 10 weeks. All patients were followed for 6 months after treatment.Results: After six weeks of treatment, complete improvement, partial improvement, and no response to treatment were 33.3%, 45% and 22% in meglumine antimoniate group and 26%, 23% and 51% in trial group, respectively. In both groups complete improvement was observed in lesions smaller than 2 cm². In lesions with partial improvement the treatment was continued up to 10 weeks and all patients were followed for six months. After six months ultimate cure rate was 52% in meglumine antimoniate group and 25% in hypertonic sodium chloride solution group.Conclusion: Injections of hypertonic sodium chloride solution has less efficacy in comparison with intra-lesional meglumine antimoniate in treatment of cutaneous leishmaniasis, but considering the good response in primary small lesions, it can be used as an alternative therapy in some special cases including small lesions and allergic reactions to meglumine antimoniate.
MA Nilforoush Zadeh; F Jaffari; B Malek Afzali
Volume 7, Issue 3 , 2004, , Pages 136-139
Abstract
Background: In spite of different methods of treatment, there is not a simple, safe and complete curative treatment for cutaneous Leishmaniasis (CL), yet. Objective: To compare the efficacy of intralesional Glucantime injection alone, with the combined triple therapy of cryotherapy, paramomycin ointment ...
Read More
Background: In spite of different methods of treatment, there is not a simple, safe and complete curative treatment for cutaneous Leishmaniasis (CL), yet. Objective: To compare the efficacy of intralesional Glucantime injection alone, with the combined triple therapy of cryotherapy, paramomycin ointment and intralesional Glucantime in the treatment of CL. Materials and methods: 157 patients with CL were randomly allocated into 2 groups, 81 patients in group 1 were injected with intralesional Glucantime (Twice a week up to healing to the lesions or maximum 6 weeks). 76 patients in group 2 were treated with Paramomycin ointment (15% in 10% urea, twice a day), cryotherapy (Maximum 3 times 2 weeks) apart and injection of intralesional Glucantime (Once a week), for the same period as group 1. Results: After 6 weeks, complete cure rate in group 2 (89.5%) was significantly more than group 1 (70.4%) (P<0.05). Conclusion: Our results indicating of more efficacy of the triple therapy is in accordance with the previous studies of combined cryotherapy and Paramomycin. It could be recommended as a better treatment modality for CL wherever possible.
AR Gholami; A Khamesipour; A Momeni; T Ghazanfari; MA Nilforoush Zadeh; Z Darajeh; Y Dowlati
Volume 3, Issue 3 , 2000, , Pages 2-6
Abstract
Background: Cutaneous leishmaniasis (CL) is a protozoan disease of the skin caused by a wide range of italic species. The disease is endemic in many countries. It has been recognized as a major public health problem in Iran. Many treatments have been suggested for it but none of them was fully effective. ...
Read More
Background: Cutaneous leishmaniasis (CL) is a protozoan disease of the skin caused by a wide range of italic species. The disease is endemic in many countries. It has been recognized as a major public health problem in Iran. Many treatments have been suggested for it but none of them was fully effective. Objective: The objective of this study was to compare the efficacy of a 5% garlic cream with placebo in CL. Patients and Methods: A double blind, placebo controlled study was performed in Isfahan and Jahrom in 1997 and 1998. 197 patients were randomly selected. Exclusion criteria were: pregnancy, lactation, age less than 5 years and duration of disease more than 100 days. Each patient received garlic cream 5% or placebo for 3 weeks and was followed for another period of 40 days. Results: The study was completed as planned in 171 patients. 96 were treated with garlic 5% cream and 75 with placebo. Complete healing occurred in 18 (18.75%) of garlic group in comparison with 15 (20%) of placebo group. The difference was not significant (P=0.9865). Conclusion: 5% garlic cream was not effective in treatment of cutaneous leishmaniasis. Further studies with higher concentrations or different vehicle are needed.
A Momeni; A Asilian; M Meghdadi; Sh Enshaieh; F Shariati; MA Nilforoush Zadeh; F Iraji; F Fatemi; M Amin Javaheri
Volume 2, Issue 1 , 1998, , Pages 21-26
Abstract
Hypersensitivity to anticonvulsant drugs have been reported many times. But anticonvulsant hypersensitivity syndrome (AHS) is a potentially fatal drug reaction with cutaneous and systemic reaction to the arene oxide-producing anticonvulsants, phenytoin, carbamazepine, and Phenobarbital sodium. The hall-mark ...
Read More
Hypersensitivity to anticonvulsant drugs have been reported many times. But anticonvulsant hypersensitivity syndrome (AHS) is a potentially fatal drug reaction with cutaneous and systemic reaction to the arene oxide-producing anticonvulsants, phenytoin, carbamazepine, and Phenobarbital sodium. The hall-mark features of this syndrome are: Fever, rash and lymphadenopathy. The epoxide hydrolase enzyme may be lacking or mutated in persons in whom AHS develops. The reaction may be genetically determined and familial occurrence of hypersensitivity was observed. The timely recognition of AHS is important, because accurate diagnosis avoids potentially fatal re-exposure and affects subsequent anticonvulsant treatment options. We report two cases of AHS and review the clinical and pathophysiologic features.